



SURYA PHARMACEUTICAL LIMITED

Registered Office: 1596, 1st Floor, Bhaglrath Palace, Chandni Chowk, Delhi - 110006 (INDIA)

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED JUNE 30, 2013

		Rs. in Lacs			
Sr. No.	PART - I Particulars	Quarter ended		Year ended	
		30.06.2013 Unaudited	31.03.2013 Audited	30.06.2012 Unaudited	31.03.2013 Audited
1	Net Sales/Income from Operations(Net of Excise Duty)	574.05	381.48	3124.46	6033.04
	Total	574.05	381.48	3124.46	6033.04
2	Expenditure				
	a. (Increase)/Decrease in Stock in Trade and WIP, FG	630.59	10149.42	(2809.52)	9093.01
	b. Consumption of Raw Materials	21.98	273.25	6604.58	9192.61
	c. Purchase of Traded Goods	-	-	-	-
	d. Employees' benefits expense	49.72	36.79	415.40	884.51
	e. Depreciation	1566.85	3399.97	926.30	6246.51
	f. Other Expenditure	180.12	589.10	1192.00	2561.40
	g. Total	2449.26	14448.53	6328.76	27978.04
3	Profit from Operations before Other Income,	(1875.21)	(14067.05)	(3204.30)	(21945.00)
	Finance Costs & Exceptional Items (1-2)				
4	Other Operating Income	-	(1864.09)	93.85	(1763.91)
5	Profit before Finance Costs & Exceptional Items (3+4)	(1875.21)	(15931.14)	(3110.45)	(23708.91)
6	Finance Costs	6180.21	3771.58	5670.88	20368.94
7	Profit after Finance Costs but before Exceptional Items (5-6)	(8055.42)	(19702.72)	(8781.33)	(44077.85)
8	Exceptional Items	-	-	-	-
9	Profit from Ordinary Activities before tax (7+8)	(8055.42)	(19702.72)	(8781.33)	(44077.85)
10	Tax expenses-Current Tax & Deferred Tax	-	-	-	14419.04
11	Net Profit from Ordinary Activities after tax (9-10)	(8055.42)	(19702.72)	(8781.33)	(29658.81)
12	Extraordinary Items	-	1792.95	-	1792.95
13	Net Profit for the period (11-12)	(8055.42)	(21495.67)	(8781.33)	(31451.76)
14	Paid-up Equity Share Capital	2027.52	2027.52	2027.52	2027.52
	(Face Value of Rs.1/- per Share)				
15	Reserves excluding Revaluation Reserves	-	-	-	(7460.51)
16	Earnings Per Share (EPS)				
	a. Basic and diluted EPS before Extraordinary items	(3.97)	(10.60)	(4.33)	(15.51)
	b. Basic and diluted EPS after Extraordinary items	(3.97)	(10.60)	(4.33)	(15.51)
PART - II		Quarter ended			
A	PARTICULARS OF SHAREHOLDING	30.06.2013	31.03.2013	30.06.2012	31.03.2013
1	Public Shareholding				
	- Number of Shares	159713656	159713656	142204998	159713656
	- Percentage of Shareholding	78.77	78.77	70.14	78.77
2	Promoter and Promoter Group Shareholding:				
	a) Pledged/Encumbered				
	- No. of Shares	41869974	41869974	59378632	41869974
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	97.28	97.28	98.07	97.28
	- Percentage of Shares (as a % of the total share Capital of the Company)	20.65	20.65	29.29	20.65
	b) Non-Encumbered				
	- No. of Shares	1168750	1168750	1168750	1168750
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	2.72	2.72	1.93	2.72
	- Percentage of Shares (as a % of the total share Capital of the Company)	0.58	0.58	0.58	0.58

For SURYA PHARMACEUTICAL LTD.

Rajiv Goyal
RAJIV GOYAL
Managing Director

	Particulars	3 months ended 30/06/2013
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0

NOTES:

- 1 The above results have not been reviewed by the Audit Committee as the said Committee does not consist of any Member as on date. The Board of Directors of the Company presently consists of two persons, which is less than the minimum number of Directors statutorily required in case of a public company. The above results have been taken on record by the two Directors of the Company i.e., Managing Director and Executive Director on September 12, 2013. The present Directors of the Company are in discussion with persons for induction as Director on the Board of Directors of the Company. The Whole time Secretary mandatorily required to hold office in case of a public company is not in office.
- 2 The Company has filed Reference under the Sick Industrial Companies (Special Provisions) Act, 1985 before the Hon'ble Board for Industrial and Financial Reconstruction for reasons of its accumulated losses as at March 31, 2013 exceeding its net worth.
- 3 Certain creditors of the Company to whom amounts are due for payment (including certain claims wherein the amounts are partly or wholly disputed by the Company) have initiated proceedings for winding up of the Company before the jurisdictional High Court, i.e., Hon'ble Delhi High Court and/or proceedings for arbitration, interalia, seeking interim relief from jurisdictional courts. The Company is contesting the above proceedings.
There exist orders for restrain issued by certain courts against the Company whereby disposal of assets / specified assets is not permitted by the Company and there also some orders of attachment of assets of the Company issued by the Income Tax Department.
- 4 Restructuring of debts of the Company carried by the lenders of the Company under Corporate Debts Restructuring forum has been unilaterally recalled by certain lenders, which has been followed up by in some cases by notice issued by lenders u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002. The Company is aggrieved against these notices and will be taking action as may be advised by its counsel.
- 5 The above results have not been reviewed by the Statutory Auditors of the Company as the Board of Directors of the Company consists of two Directors, which does not constitute a valid quorum to review and approve the above accounts.
- 6 The Company operates in only one segment.
- 7 Figures have been regrouped/rearranged wherever considered necessary.

For and on behalf of the Board of Directors
For Surya Pharmaceutical Limited



RAJIV GOYAL
(Chairman & Managing Director)

Place: Chandigarh
Date: September 12, 2013